Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Unloaded 5,222 Shares?

UroGen Pharma's Chief Medical Officer Mark Schoenberg sold 5,222 shares for approximately $143,000 on June 8, 2026, reducing his holdings by 3.60%. While his remaining stake of 139,763 shares keeps his interests aligned with investors, the sale follows a pattern of regular dispositions over the past year. The company faces headwinds from an upcoming generic competition agreement with Teva Pharmaceuticals for its flagship drug Jelmyto starting September 2030, though growth in other products like Zusduri may offset losses.

06/14/2026, 11:14 AM • The Motley Fool

UroGen Applauds BCAN’s New Faces of Bladder Cancer Report Highlighting Recurrence Burden and Fear of Recurrence

A national survey of over 1,100 bladder cancer patients conducted by the Bladder Cancer Advocacy Network (BCAN) reveals that nearly 80% of patients report fear of recurrence, with rates exceeding 90% among those under 50. The report documents significant procedural burden, with many patients undergoing five or more cystoscopies. UroGen Pharma commended the findings, emphasizing the need for treatment approaches that consider long-term quality of life alongside tumor control.

03/13/2026, 8:00 AM • GlobeNewswire

Bladder Cancer Patients Report Delayed Diagnosis and Gaps in Support

A comprehensive survey of over 1,100 bladder cancer patients reveals significant gaps in care despite advances in treatment. Key findings include diagnostic delays for women (45% initially misdiagnosed with UTIs), inadequate mental health support (41% never offered resources), and financial barriers affecting treatment decisions, particularly for younger patients.

03/13/2026, 7:00 AM • GlobeNewswire

Billionaire Family Office Dumps All of Its UroGen Stock Amid 100% Rally

Wildcat Capital Management, the family office of late billionaire David Bonderman, completely exited its position in UroGen Pharma by selling 495,606 shares worth $6.79 million in Q3. Despite UroGen's impressive 113% one-year rally, the exit signals disciplined profit-taking rather than loss of confidence, as biotech winners often see valuation risk increase after strong rallies.

12/26/2025, 1:19 PM • The Motley Fool

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

UroGen Pharma granted restricted stock units to 14 new employees to support commercialization of Jelmyto and ZUSDURI, with up to 32,500 ordinary shares issuable upon vesting over three years.

12/05/2025, 8:00 AM • GlobeNewswire

UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference

UroGen Pharma will present at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, in a fireside chat format, discussing their innovative cancer treatment technologies.

11/25/2025, 8:00 AM • GlobeNewswire

ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non–Muscle Invasive Bladder Cancer

UroGen Pharma published a comprehensive review highlighting the clinical efficacy of ZUSDURI, an FDA-approved treatment for recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer, demonstrating high complete response rates and a manageable safety profile.

10/02/2025, 8:00 AM • GlobeNewswire

UROGEN DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds UroGen Pharma (URGN) Investors of the July 28th Deadline and Urges Investors to Inquire About Their Rights in Class Action Lawsuit

A class action lawsuit has been filed against UroGen Pharma regarding its UGN-102 drug application, alleging misleading statements about clinical study design and FDA approval risks. The stock price dropped significantly after FDA advisory committee voted against drug approval.

07/21/2025, 7:39 PM • GlobeNewswire

UROGEN ALERT: Bragar Eagel & Squire, P.C. Urges Investors in UroGen Pharma (URGN) to Inquire About Their Rights in Class Action Lawsuit

A class action lawsuit has been filed against UroGen Pharma regarding its UGN-102 drug application, alleging misleading statements about clinical study design and FDA approval risks.

07/19/2025, 10:58 AM • GlobeNewswire

UROGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the Class Action Lawsuit Against UroGen Pharma Ltd. And Encourages Investors to Contact the Firm

A class action lawsuit has been filed against UroGen Pharma regarding its UGN-102 drug application, alleging misleading statements about clinical study design and FDA approval risks.

07/15/2025, 7:35 PM • GlobeNewswire

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Red Cat, Organon, UroGen and Fortrea and Encourages Investors to Contact the Firm

Law firm Bragar Eagel & Squire, P.C. has filed class action lawsuits against Organon, UroGen, Red Cat, and Fortrea, alleging misleading statements and financial misrepresentations that negatively impacted investor interests.

07/12/2025, 3:01 PM • GlobeNewswire

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Red Cat, Reckitt, UroGen and Fortrea and Encourages Investors to Contact the Firm

Law firm Bragar Eagel & Squire announced class action lawsuits against Reckitt, UroGen, Red Cat, and Fortrea for alleged misleading statements and financial misrepresentations during specified class periods.

07/07/2025, 9:00 PM • GlobeNewswire

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Red Cat, Reckitt, UroGen and Fortrea and Encourages Investors to Contact the Firm

Law firm Bragar Eagel & Squire, P.C. reminds investors of class action lawsuits filed against Reckitt, UroGen, Red Cat, and Fortrea, alleging misleading statements and financial misrepresentations.

06/30/2025, 9:00 PM • GlobeNewswire

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Red Cat, Reckitt, UroGen and Fortrea and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. has filed class action lawsuits against several companies, including Red Cat, Reckitt, UroGen, and Fortrea, on behalf of their stockholders.

06/23/2025, 9:00 PM • GlobeNewswire